Seth M. Pollack

4.9k citations

120 papers · 2.2k indexed · h-index 27

Impact in

Oncology top 2%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Vascular Tumors and Angiosarcomas
Pulmonary and Respiratory Medicine top 2%
- Sarcoma Diagnosis and Treatment

Papers in ⓘ

Oncology 74
- CAR-T cell therapy research 41
- Vascular Tumors and Angiosarcomas 21
- Cancer Immunotherapy and Biomarkers 13
Pulmonary and Respiratory Medicine 70
- Sarcoma Diagnosis and Treatment 64

Co-authors: Robin L. Jones (51 shared papers)Elizabeth T. Loggers (30 shared papers)Eve T. Rodler (10 shared papers)Lee D. Cranmer (22 shared papers)Cassian Yee (8 shared papers)Venu G. Pillarisetty (10 shared papers)Michael J. Wagner (17 shared papers)Emanuela Palmerini (3 shared papers)
Journals: Journal of Clinical Oncology (26 papers)Cancers (7 papers)Journal for ImmunoTherapy of Cancer (5 papers)Clinical Cancer Research (3 papers)American Society of Clinical Oncology Educational Book (3 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Seth M. Pollack

111 papers receiving 2.1k citations

Peers

Countries citing papers authored by Seth M. Pollack

Since Specialization

Citations

This map shows the geographic impact of Seth M. Pollack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seth M. Pollack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seth M. Pollack more than expected).

Fields of papers citing papers by Seth M. Pollack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seth M. Pollack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seth M. Pollack. The network helps show where Seth M. Pollack may publish in the future.

Co-authors

The 25 scholars most cited alongside Seth M. Pollack, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Seth M. Pollack Line = papers co-authored together Seth M. Pollack links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 120 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer Clinical Cancer Research ·Yongwoo David Seo, Xiuyun Jiang, Kevin M. Sullivan, Florencia G. Jalikis, Kimberly S. Smythe, Arezou Abbasi, Marissa Vignali, James O. Park, Sara K. Daniel, Seth M. Pollack, Teresa S. Kim, Raymond S. Yeung, Ian Nicholas Crispe, Robert H. Pierce, Harlan Robins, Venu G. Pillarisetty	2019	170
2	Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial Cancer Immunology Research ·Shihong Zhang, Karan Kohli, Graeme Black, Yao Lu, Sydney M. Spadinger, Qianchuan He, Venu G. Pillarisetty, Lee D. Cranmer, Brian A. Van Tine, Cassian Yee, Robert H. Pierce, Stanley R. Riddell, Robin L. Jones, Seth M. Pollack	2019	101
3	NY‐ESO‐1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma Cancer ·Seth M. Pollack, Achim A. Jungbluth, Benjamin Hoch, Erik Farrar, Marie Bleakley, David J. Schneider, Elizabeth T. Loggers, Eve T. Rodler, Janet F. Eary, Ernest U. Conrad, Robin L. Jones, Cassian Yee	2012	101
4	Pancreatic Ductal Adenocarcinoma Contains an Effector and Regulatory Immune Cell Infiltrate that Is Altered by Multimodal Neoadjuvant Treatment PLoS ONE ·Kendall C. Shibuya, Vikas Goel, Wei Xiong, Jonathan G. Sham, Seth M. Pollack, Allison M. Leahy, Samuel H. Whiting, Matthew M. Yeh, Cassian Yee, Stanley R. Riddell, Venu G. Pillarisetty	2014	99
5	Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma JAMA Oncology ·Seth M. Pollack, Mary W. Redman, Kelsey K. Baker, Michael J. Wagner, Brett Schroeder, Elizabeth T. Loggers, Kathryn Trieselmann, Vanessa C. Copeland, Shihong Zhang, Graeme Black, Sabrina McDonnell, Jeffrey Gregory, Rylee Johnson, Roxanne Moore, Robin L. Jones, Lee D. Cranmer	2020	97
6	Novel Therapeutic Approaches in Chondrosarcoma Future Oncology ·Genovefa Polychronidou, Vasilios Karavasilis, Seth M. Pollack, Paul H. Huang, Alex Pui‐Wai Lee, Robin L. Jones	2017	80
7	Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone BMC Cancer ·Emanuela Palmerini, Robin L. Jones, Emanuela Marchesi, Anna Paioli, Marilena Cesari, Alessandra Longhi, Cristina Meazza, Luca Coccoli, Franca Fagioli, Sebastian Dorin Asaftei, Giovanni Grignani, A. Tamburini, Seth M. Pollack, Piero Picci, S. Ferrari	2016	72
8	First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1 Clinical Cancer Research ·Neeta Somaiah, Matthew S. Block, Joseph W. Kim, Geoffrey I. Shapiro, T. Khanh, Patrick Hwu, Joseph P. Eder, Robin L. Jones, Hailing Lu, Jan H. ter Meulen, Chet Bohac, Michael Chen, Frank J. Hsu, Sacha Gnjatic, Seth M. Pollack	2019	71
9	A Contemporary Large Single-Institution Evaluation of Resected Retroperitoneal Sarcoma Annals of Surgical Oncology ·Prashoban Bremjit, Robin L. Jones, Xiaoyu Chai, Gabrielle Kane, Eve T. Rodler, Elizabeth T. Loggers, Seth M. Pollack, Venu G. Pillarisetty, Gary N. Mann	2014	63
10	Emerging Targeted and Immune-Based Therapies in Sarcoma Journal of Clinical Oncology ·Seth M. Pollack, Matthew Ingham, Matthew B. Spraker, Gary K. Schwartz	2017	61
11	More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven Treatments American Society of Clinical Oncology Educational Book ·Daniela Katz, Emanuela Palmerini, Seth M. Pollack	2018	56
12	MRI Radiomic Features Are Independently Associated With Overall Survival in Soft Tissue Sarcoma Advances in Radiation Oncology ·Matthew B. Spraker, Landon S. Wootton, Daniel S. Hippe, Kevin C. Ball, Jan C. Peeken, Meghan W. Macomber, Tobias R. Chapman, Michael N. Hoff, Edward Y. Kim, Seth M. Pollack, Stephanie E. Combs, Matthew J. Nyflot	2019	54
13	First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient Journal of Immunotherapy ·Seth M. Pollack, Hailing Lu, Sacha Gnjatic, Neeta Somaiah, Ryan B. O’Malley, Robin L. Jones, Frank J. Hsu, Jan ter Meulen	2017	47
14	NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycitabine PLoS ONE ·Seth M. Pollack, Yonqing Li, Megan J. Blaisdell, Erik Farrar, Jeffrey Chou, Benjamin Hoch, Elizabeth T. Loggers, Eve T. Rodler, Janet F. Eary, Ernest U. Conrad, Robin L. Jones, Cassian Yee	2012	45
15	Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells Journal for ImmunoTherapy of Cancer ·Seth M. Pollack, Robin L. Jones, Erik Farrar, Ivy Lai, Sylvia M. Lee, Jianhong Cao, Venu G. Pillarisetty, Benjamin Hoch, Ashley Gullett, Marie Bleakley, Ernest U. Conrad, Janet F. Eary, Kendall C. Shibuya, Edus H. Warren, Jason N Carstens, Shelly Heimfeld, Stanley R. Riddell, Cassian Yee	2014	42
16	The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients Expert Review of Vaccines ·Seth M. Pollack	2017	40
17	Epigenetic Modulation to Enable Antigen-specific T-cell Therapy of Colorectal Cancer Journal of Immunotherapy ·Jeffrey Chou, Lilien N. Voong, Christie Mortales, Andrea Towlerton, Seth M. Pollack, Xiaoji Chen, Cassian Yee, Paul F. Robbins, Edus H. Warren	2012	39
18	Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics Human Pathology ·George Jour, John D. Scarborough, Robin L. Jones, Elizabeth T. Loggers, Seth M. Pollack, Colin C. Pritchard, Benjamin Hoch	2014	38
19	Diagnosis, prognosis, and management of leiomyosarcoma Current Opinion in Oncology ·Andrew J. Bathan, Anastasia Constantinidou, Seth M. Pollack, Robin L. Jones	2013	36
20	Optimising Cancer Vaccine Design in Sarcoma Cancers ·Alexandra Pender, Robin L. Jones, Seth M. Pollack	2018	36

About Seth M. Pollack

Seth M. Pollack is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Immunology, Gastroenterology and Rheumatology, having authored 120 papers that have together received 2.2k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (64 papers), CAR-T cell therapy research (41 papers), Immunotherapy and Immune Responses (33 papers), Vascular Tumors and Angiosarcomas (21 papers), Virus-based gene therapy research (13 papers), Cancer Immunotherapy and Biomarkers (13 papers), Bone Tumor Diagnosis and Treatments (13 papers) and Immune Cell Function and Interaction (11 papers). The work is most often cited by research in Oncology (1.3k citations), Pulmonary and Respiratory Medicine (1.1k citations), Immunology (651 citations), Rheumatology (262 citations) and Gastroenterology (85 citations). Seth M. Pollack has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Robin L. Jones, Elizabeth T. Loggers, Eve T. Rodler, Lee D. Cranmer, Cassian Yee, Venu G. Pillarisetty, Michael J. Wagner, Emanuela Palmerini, Paul H. Huang and Robert H. Pierce. Their work appears in journals such as Journal of Clinical Oncology, Cancers, Journal for ImmunoTherapy of Cancer, Clinical Cancer Research and American Society of Clinical Oncology Educational Book.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact